Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Doxorubicin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP2A known ✓ | P11388 | 5/20 | 1.00 |
| ▸ | MEN1 | O00255 | 9/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 9/20 | 1.00 |
| ▸ | THRB | P10828 | 8/20 | 1.00 |
| ▸ | BLM | P54132 | 8/20 | 1.00 |
| ▸ | RECQL | P46063 | 7/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 6/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 6/20 | 1.00 |
| ▸ | BRCA1 | P38398 | 6/20 | 1.00 |
| ▸ | MAPT | P10636 | 6/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 4/20 | 1.00 |
| ▸ | STAT6 | P42226 | 4/20 | 1.00 |
| ▸ | HTT | P42858 | 4/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 3/20 | 1.00 |
| ▸ | TBXA2R | P21731 | 3/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 1.00 |
| ▸ | ABCB1 | P08183 | 3/20 | 1.00 |
| ▸ | PTGS1 | P23219 | 3/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Epirubicin SCHEMBL13863672 | 1.00 | MEN1 (1.00) | MEN1KMT2ATHRBBLMRECQL | |
| Epirubicin SCHEMBL13575791 | 1.00 | MEN1 (1.00) | MEN1KMT2ATHRBBLMRECQL | |
| Epirubicin SCHEMBL21184881 | 1.00 | MEN1 (1.00) | MEN1KMT2ATHRBBLMRECQL | |
| Epirubicin SCHEMBL4100091 | 1.00 | MEN1 (1.00) | MEN1KMT2ATHRBBLMRECQL | |
| Epirubicin SCHEMBL24421866 | 1.00 | MEN1 (1.00) | MEN1KMT2ATHRBBLMRECQL | |
| Doxorubicin SCHEMBL3243 | 1.00 | MEN1 (1.00) | MEN1KMT2ATHRBBLMRECQL | |
| Epirubicin SCHEMBL23365786 | 1.00 | MEN1 (1.00) | MEN1KMT2ATHRBBLMRECQL | |
| Epirubicin SCHEMBL22403027 | 1.00 | MEN1 (1.00) | MEN1KMT2ATHRBBLMRECQL | |
| Epirubicin SCHEMBL21914951 | 1.00 | MEN1 (1.00) | MEN1KMT2ATHRBBLMRECQL | |
| Epirubicin SCHEMBL22291815 | 1.00 | MEN1 (1.00) | MEN1KMT2ATHRBBLMRECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106667911-A | Amphiphilic polyurethane self-assembly nanoparticles and preparation and application thereof | 东华大学 | 2017-05-17 | — | — | CN | claimed |
| US-8580782-B2 | Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2013-11-12 | — | — | US | claimed |
| CN-111212647-B | Dihydro oxadiazinones | 拜耳股份有限公司 | 2024-05-14 | — | — | CN | disclosed |
| US-20240148740-A1 | COMBINATION OF AN AHR INHIBITOR WITH A PDX INHIBITOR OR DOXORUBICINE | PAHR THERAPEUTICS, INC. | 2024-05-09 | — | — | US | disclosed |
| WO-2024004656-A1 | EFFECT OF INHIBITING IMMUNE-RELATED ADVERSE EVENT | 国立大学法人東北大学 | 2024-01-04 | — | — | WO | disclosed |
| CN-117069786-A | Phospholipid derivative, liposome and application thereof | 五邑大学 | 2023-11-17 | — | — | CN | disclosed |
| CN-116848094-A | Tertiary amine lipid compounds and uses thereof | 华南理工大学 | 2023-10-03 | — | — | CN | disclosed |
| CN-116761610-A | AHR inhibitors and uses thereof | 医肯纳肿瘤学公司 | 2023-09-15 | — | — | CN | disclosed |
| EP-4236960-A1 | COMBINATION OF AN AHR INHIBITOR WITH A PDX INHIBITOR OR DOXORUBICINE | Ikena Oncology, Inc. (US) | 2023-09-06 | — | — | EP | disclosed |
| WO-2023125184-A1 | TERTIARY AMINE LIPID COMPOUND AND USE THEREOF | 华南理工大学 | 2023-07-06 | — | — | WO | disclosed |
| CN-112933046-B | Adriamycin prodrug active drug-loaded liposome and preparation method and application thereof | 沈阳药科大学 | 2023-01-24 | — | — | CN | disclosed |
| CN-101163485-A | Method for treating advanced ovarian cancer with doxorubicin entrapped in liposomes | ALZA CORP (US) | 2008-04-16 | — | — | CN | disclosed |
| CN-100367931-C | Method of drug loading in liposomes by gradient | GILEAD SCIENCES INC (US) | 2008-02-13 | — | — | CN | disclosed |
| CN-100367932-C | Method of drug loading in liposomes by gradient | GILEAD SCIENCES INC (US) | 2008-02-13 | — | — | CN | disclosed |
| EP-1874324-A1 | METHOD FOR TREATING ADVANCED OVARIAN CANCER WITH DOXORUBICIN ENTRAPPED IN LIPOSOMES | Alza Corporation (US) | 2008-01-09 | — | — | EP | disclosed |
| US-20070026060-A1 | Method for treating advanced ovarian cancer | UNIVERSITY OF ALABAMA | 2007-02-01 | — | — | US | disclosed |
| WO-2006116341-A1 | METHOD FOR TREATING ADVANCED OVARIAN CANCER WITH DOXORUBICIN ENTRAPPED IN LIPOSOMES | ALZA CORPORATION (US) | 2006-11-02 | — | — | WO | disclosed |
| CN-1717221-A | Method of drug loading in liposomes by gradient | GILEAD SCIENCES INC (US) | 2006-01-04 | — | — | CN | disclosed |
| CN-1717222-A | Method of drug loading in liposomes by gradient | GILEAD SCIENCES INC (US) | 2006-01-04 | — | — | CN | disclosed |
| WO-1999058111-A1 | METHODS OF USING LIPID BASED DRUG DELIVERY VEHICLES | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 1999-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240148740-A1 | COMBINATION OF AN AHR INHIBITOR WITH A PDX INHIBITOR OR DOXORUBICINE | AHR, ARNT, AIPL1 | TOP2A 869/4885MEN1 4798/4885KMT2A 104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.